A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study will utilize Erwinaze via intravenous administration in patients between the ages
of 1 and 30 who have experienced an allergy to their frontline therapy. The study will
determine the proportion of patients with 2 day nadir serum asparaginase activity levels that
are >0.1 IU/mL during the first 2 weeks of treatment with 3 times per week IV dosing.